Guerbet's Lipiodol Ultra Fluid gets new indications

2019 04 24 16 07 7784 Guerbet Rsna 2018 400

Contrast developer Guerbet has received approval for new indications of its Lipiodol Ultra Fluid contrast agent in Switzerland and India for use in the treatment of intermediate-stage hepatocellular carcinoma (HCC).

Lipiodol Ultra Fluid has been approved for the chemoembolization (cTACE) of intermediate-stage HCC tumors in adults. cTACE is a minimally invasive procedure that consists of mixing Lipiodol Ultra Fluid with an anticancer drug. The mixture is injected trans-arterially in the liver as a locoregional targeted chemotherapy for unresectable liver tumors, with Lipiodol Ultra Fluid acting as a contrast agent, a drug-eluting vehicle, and a dual arterio-portal transient embolic.

The cTACE indication has already been approved for Lipiodol Ultra Fluid in several other countries in the Europe, Middle East, and Africa (EMEA) region.

Page 1 of 540
Next Page